Ironwood Pharmaceuticals   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Cambridge MA United States (1998)

Organization Overview

First Clinical Trial
2006
NCT00258193
First Marketed Drug
2015
lesinurad (zurampic)
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Ironwood Pharmaceuticals | Ironwood Pharmaceuticals, Inc. | IRONWOOD PHARMS INC | Microbia | Microbia, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Abdominal Pain (Phase 2)

Albuminuria (Phase 2)

Anemia, Sickle Cell (Phase 2)

Constipation (Phase 4)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Diabetic Nephropathies (Phase 2)

Diarrhea (Phase 2)

Digestive System Diseases (Phase 2)

Dyspepsia (Phase 2)

Esophageal Achalasia (Phase 2)

Esophagitis, Peptic (Phase 3)

Gastroesophageal Reflux (Phase 3)

Gastrointestinal Diseases (Phase 2)

Gastroparesis (Phase 2)

Gout (Phase 4)

Heart Failure (Phase 2)

Hypercholesterolemia (Phase 2)

Hypertension (Phase 2)

Irritable Bowel Syndrome (Phase 4)

Kidney Diseases (Phase 4)

Renal Insufficiency, Chronic (Phase 4)

Syndrome (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 49
  • # of Trial APIs: 18